Exemplification of the challenges associated with utilising fluorescence intensity based assays in discovery

Importance of the field: Despite the advances in the understanding of biological processes, significant challenges still face those engaged in small molecule drug discovery. To complicate matters further, researchers are often overwhelmed with a range of off-the-shelf as well as bespoke assay formats to choose from when initiating a drug discovery programme. Although fluorescence intensity based assays have traditionally been adopted in drug discovery programmes for a wide range of target classes, it is essential to fully validate the chosen readouts to confirm that they accurately reflect the underlying biological mechanism under investigation. Areas covered in this review: This review exemplifies the challenges that are often encountered with fluorescence intensity based assays and particular attention is paid to compound interference, the protease, deacetylating enzyme and kinase enzyme target classes. What the reader will gain: Designing a critical path in early stage drug discovery, which combines several diverse and minimally overlapping readout modes, will maximise the chance that compound activities will translate between the primary assay (utilised in the initial screening campaign) and secondary assay (utilised to evaluate the confirmed hits identified in the primary assay, usually a cell based assay) formats in a meaningful way. However, this is not always the case as is amply demonstrated across both academia and the pharmaceutical industry. Paying insufficient attention to these points can lead to the early termination of drug discovery programmes, not for want of resources or confidence in the rationale underlying the target, but instead because decision making has been driven by assay data originating from a different biological mechanism than the one under investigation. Take home message: Although fluorescence intensity based assays are likely to remain popular for many target classes in drug discovery, in particular in small molecule screening campaigns, it is essential that at the outset they are sufficiently well validated so that compounds are likely to exhibit profiles that are confirmed in subsequent assays.

[1]  M. Weir.  Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering? , 2007, Current opinion in nephrology and hypertension.

[2]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[3]  A. Berger,et al.  Mapping the active site of papain with the aid of peptide substrates and inhibitors. , 1970, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[4]  Venkataraman Thanabal,et al.  SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1♦ , 2010, The Journal of Biological Chemistry.

[5]  C. Fahy,et al.  Processing of peptide and hormone precursors at the dibasic cleavage sites , 2009, Cellular and Molecular Life Sciences.

[6]  P. Coleman,et al.  Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. , 1981, Methods in enzymology.

[7]  Roland Martin.  Multiple sclerosis: Closing in on an oral treatment , 2010, Nature.

[8]  V. Schramm,et al.  SIR2: the biochemical mechanism of NAD(+)-dependent protein deacetylation and ADP-ribosyl enzyme intermediates. , 2004, Current medicinal chemistry.

[9]  A. Hopkins,et al.  Navigating chemical space for biology and medicine , 2004, Nature.

[10]  Xiayang Qiu,et al.  Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia , 2007, Nature Structural &Molecular Biology.

[11]  Eric David,et al.  Pharmaceutical R&D: the road to positive returns , 2009, Nature Reviews Drug Discovery.

[12]  G. Baldwin,et al.  Peptide processing and biology in human disease , 2009, Current opinion in endocrinology, diabetes, and obesity.

[13]  A. Berger,et al.  On the active site of proteases. 3. Mapping the active site of papain; specific peptide inhibitors of papain. , 1968, Biochemical and biophysical research communications.

[14]  Walters Wp,et al.  Guiding molecules towards drug-likeness. , 2002 .

[15]  Brian C. Smith,et al.  Mechanisms and molecular probes of sirtuins. , 2008, Chemistry & biology.

[16]  Dependence of the P2-S2 stereochemical selectivity of papain on the nature of the catalytic-site chemistry. Quantification of selectivity in the catalysed hydrolysis of the enantiomeric N-acetylphenylalanylglycine 4-nitroanilides. , 1990, The Biochemical journal.

[17]  Amy V. Lynch,et al.  Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes , 2007, Nature.

[18]  Mariano Ruiz Espejo.  Book Review: Clinical trials. A methodologic perspective, 2nd edition , 2006 .

[19]  J. Kraut,et al.  An x-ray crystallographic study of the binding of peptide chloromethyl ketone inhibitors to subtilisin BPN'. , 1972, Biochemistry.

[20]  J. Kraut,et al.  Polypeptide halomethyl ketones bind to serine proteases as analogs of the tetrahedral intermediate. X-ray crystallographic comparison of lysine- and phenylalanine-polypeptide chloromethyl ketone-inhibited subtilisin. , 1976, The Journal of biological chemistry.

[21]  Sergei A Eremin,et al.  Fluorescence polarization immunoassays and related methods for simple, high-throughput screening of small molecules , 2008, Analytical and bioanalytical chemistry.

[22]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[23]  Christopher P Austin,et al.  Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. , 2010, Journal of medicinal chemistry.

[24]  B. Munos.  Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[25]  N. Hooper,et al.  Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor , 2009, The Biochemical journal.

[26]  B. Ozenberger,et al.  Functional characterization of Narc 1, a novel proteinase related to proteinase K. , 2003, Archives of biochemistry and biophysics.

[27]  C. Craik,et al.  Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Christopher P Austin,et al.  A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.

[29]  C. G. Knight.  [2] Fluorimetric assays of proteolytic enzymes , 1995 .

[30]  R. Parker,et al.  Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[31]  Phuong Chung,et al.  Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan , 2003, Nature.

[32]  David A. Calhoun,et al.  Drugs targeting the renin–angiotensin–aldosterone system , 2002, Nature Reviews Drug Discovery.

[33]  C. G. Knight.  Fluorimetric assays of proteolytic enzymes. , 1995, Methods in enzymology.

[34]  C. Porte,et al.  Saquinavir, the pioneer antiretroviral protease inhibitor , 2009, Expert opinion on drug metabolism & toxicology.

[35]  J. Holst,et al.  Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? , 2004, Expert opinion on investigational drugs.

[36]  John T. Powers,et al.  Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors , 2010, Nature.

[37]  K. Pruitt,et al.  The role of sirtuin proteins in obesity. , 2008, Pathophysiology : the official journal of the International Society for Pathophysiology.

[38]  E. Trinquet,et al.  HTRF: A Technology Tailored for Drug Discovery –A Review of Theoretical Aspects and Recent Applications , 2009, Current chemical genomics.

[39]  G. Feuerstein,et al.  The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality. , 2009, Biochemical pharmacology.

[40]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.

[41]  L. Lau,et al.  Fas-Mediated Apoptosis Is Regulated by the Extracellular Matrix Protein CCN1 (CYR61) In Vitro and In Vivo , 2009, Molecular and Cellular Biology.

[42]  V. Kaushik,et al.  Mass spectrometric techniques for label-free high-throughput screening in drug discovery. , 2007, Analytical chemistry.

[43]  M. Murcko,et al.  Guiding molecules towards drug-likeness. , 2002, Current opinion in drug discovery & development.

[44]  Andrew B. Hughes.  Amino acids, peptides and proteins in organic chemistry , 2009 .

[45]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[46]  D. Sinclair,et al.  Mammalian sirtuins: biological insights and disease relevance. , 2010, Annual review of pathology.

[47]  S. Oparil,et al.  Purification and assay methods for angiotensin-converting enzyme. , 1996, Journal of chromatography. A.

[48]  S. Piantadosi.  Clinical Trials : A Methodologic Perspective , 2005 .

[49]  N. Hooper,et al.  A broad‐spectrum fluorescence‐based peptide library for the rapid identification of protease substrates , 2006, Proteomics.

[50]  M. Bottomley,et al.  Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants* , 2009, Journal of Biological Chemistry.

[51]  O. Ornatsky,et al.  Development of inductively coupled plasma-mass spectrometry-based protease assays. , 2010, Analytical biochemistry.

[52]  Shu-Chen Lu,et al.  Resveratrol is Not a Direct Activator of SIRT1 Enzyme Activity , 2009, Chemical biology & drug design.

[53]  A. Prat,et al.  The activation and physiological functions of the proprotein convertases. , 2008, The international journal of biochemistry & cell biology.

[54]  C. Betzel,et al.  Three-dimensional structure of proteinase K at 0.15-nm resolution. , 1988, European journal of biochemistry.

[55]  Andreas Sewing,et al.  Fluorescence readouts in HTS: no gain without pain? , 2003, Drug discovery today.

[56]  M J Todd,et al.  Enzyme kinetics determined using calorimetry: a general assay for enzyme activity? , 2001, Analytical biochemistry.

[57]  Jacques Neefjes,et al.  Fluorescent probes for proteolysis: Tools for drug discovery , 2004, Nature Reviews Drug Discovery.

[58]  M. Hsu,et al.  Mechanism of the Maturation Process of SARS-CoV 3CL Protease , 2005, Journal of Biological Chemistry.

[59]  Ronald T Raines,et al.  Bright ideas for chemical biology. , 2008, ACS chemical biology.

[60]  Taosheng Chen,et al.  A Practical Guide to Assay Development and High-Throughput Screening in Drug Discovery , 2009 .

[61]  James Inglese,et al.  A specific mechanism for nonspecific activation in reporter-gene assays. , 2008, ACS chemical biology.

[62]  K Dodgson,et al.  A 100K well screen for a muscarinic receptor using the Epic® label-free system – a reflection on the benefits of the label-free approach to screening seven-transmembrane receptors , 2009, Journal of receptor and signal transduction research.

[63]  D. Fairlie,et al.  Protease inhibitors in the clinic. , 2005, Medicinal chemistry (Shariqah (United Arab Emirates)).